| Dr Benedict Ekundayo Idowu Sr, DO | |
|
3636 S Sherwood Forest Blvd Ste 650, Baton Rouge, LA 70816-5216 | |
| (225) 756-2180 | |
| (225) 756-2179 |
| Full Name | Dr Benedict Ekundayo Idowu Sr |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 32 Years |
| Location | 3636 S Sherwood Forest Blvd Ste 650, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134177645 | NPI | - | NPPES |
| 1997561 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 021809 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beauregard Memorial Hospital | Deridder, LA | Hospital |
| Prevost Memorial Hospital | Donaldsonville, LA | Hospital |
| Ochsner Medical Center - Baton Rouge | Baton rouge, LA | Hospital |
| Entity Name | Correct Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987441 PECOS PAC ID: 8628980992 Enrollment ID: O20040816000150 |
News Archive
Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.
With marathon trainees about to take to the streets of Chicago this Sunday, Loyola University Health System registered dietitian Brooke Schantz offers the top 10 nutrition tips runners can follow to help them cross the finish line.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
› Verified 2 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20140930001176 |
News Archive
Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.
With marathon trainees about to take to the streets of Chicago this Sunday, Loyola University Health System registered dietitian Brooke Schantz offers the top 10 nutrition tips runners can follow to help them cross the finish line.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
› Verified 2 days ago
| Entity Name | South Central Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427611854 PECOS PAC ID: 6507195492 Enrollment ID: O20191022002061 |
News Archive
Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.
With marathon trainees about to take to the streets of Chicago this Sunday, Loyola University Health System registered dietitian Brooke Schantz offers the top 10 nutrition tips runners can follow to help them cross the finish line.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
› Verified 2 days ago
| Entity Name | Ess Of Ferriday Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346900560 PECOS PAC ID: 2769876275 Enrollment ID: O20220228000365 |
News Archive
Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.
With marathon trainees about to take to the streets of Chicago this Sunday, Loyola University Health System registered dietitian Brooke Schantz offers the top 10 nutrition tips runners can follow to help them cross the finish line.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Benedict Ekundayo Idowu Sr, DO 3684 S Cottages Ave, Baton Rouge, LA 70816-2790 Ph: (504) 858-5553 | Dr Benedict Ekundayo Idowu Sr, DO 3636 S Sherwood Forest Blvd Ste 650, Baton Rouge, LA 70816-5216 Ph: (225) 756-2180 |
News Archive
Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.
With marathon trainees about to take to the streets of Chicago this Sunday, Loyola University Health System registered dietitian Brooke Schantz offers the top 10 nutrition tips runners can follow to help them cross the finish line.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
› Verified 2 days ago
Dr. Donna Brian Fargason, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 9311a Bluebonnet Blvd, Baton Rouge, LA 70810 Phone: 225-769-5551 Fax: 225-769-5583 | |
Kishore M Gadde, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 6400 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-763-2552 | |
Joseph Anthony Grizzaffi Jr., M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5131 Odonovan Dr, Ste 300, Baton Rouge, LA 70808 Phone: 225-374-0400 Fax: 225-374-0430 | |
Abdul Baset Khan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 9001 Summa Ave, Baton Rouge, LA 70809 Phone: 225-761-5200 Fax: 225-761-5654 | |
Gerard Dynes, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Dr. Kari Akili Jones, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7521 Kings Hill Ave, Baton Rouge, LA 70810 Phone: 225-267-7141 | |
Dr. Ashok Reddy Polu, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5000 Hennessy Blvd, Baton Rouge, LA 70808 Phone: 225-765-6565 |